Form 4: Calidi CFO Buys Shares & Warrants in Public Offering

Calidi Biotherapeutics' CFO, Andrew C. Jackson, acquired 2,500 common shares and accompanying warrants in a public offering on August 21, 2025, for $2.00 per unit.

Summary

• Andrew C. Jackson, Chief Financial Officer of Calidi Biotherapeutics, Inc. (CLDI), acquired 2,500 shares of common stock and 2,500 warrants.
• The transaction occurred on August 21, 2025, as part of a public offering conducted by the Issuer.
• Each common share was purchased with an accompanying warrant for a price of $2.00 per share and warrant.
• The warrants have an exercise price of $2.00, become exercisable on August 21, 2025, and expire on August 21, 2030.
• The acquisition was made pursuant to a contract, instruction, or written plan for the purchase of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The insider purchase by the CFO, especially in a public offering, suggests strong management confidence in the company's valuation and future, which is a positive signal for investors.

Positives

• Insider buying by the Chief Financial Officer signals management's confidence in the company's future prospects.
• Participation in a public offering by a key executive demonstrates alignment of interests with other investors in the offering.

Future Outlook

The transaction, reported with a future date of August 21, 2025, indicates a pre-planned acquisition under a Rule 10b5-1(c) plan, reflecting a structured approach to insider equity participation.

Management Comments

• The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025.
• Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant.

Industry Context

Insider purchases, particularly by a Chief Financial Officer, are generally viewed as a positive signal in the biotechnology industry, suggesting management's belief in the company's long-term value and prospects, especially following a public offering.

Comparison to Industry Standards

• Insider participation in public offerings is a common practice and is generally viewed favorably by the market as it aligns management's interests with those of shareholders.
• While specific comparable companies or projects are not detailed in this filing, the act of an executive purchasing shares in an offering is a standard indicator of confidence.

Corporate Governance

Related Party Transactions

• Andrew C. Jackson, Chief Financial Officer, acquired common stock and warrants from Calidi Biotherapeutics, Inc. in a public offering, which constitutes a transaction between a company and a related party (an executive).

Stakeholder Impact

• Shareholders: May view the CFO's purchase as a positive signal of management's belief in the company's value, potentially increasing investor confidence.
• Employees: Could interpret the executive's investment as a sign of stability and positive future outlook for the company.

Key Dates

Recommendation

The purchase of shares and warrants by the Chief Financial Officer signals management's confidence in Calidi Biotherapeutics' future. While insider buying is generally a positive indicator, a single Form 4 filing does not provide sufficient information for a strong buy or sell recommendation, warranting a 'hold' for further evaluation of the company's broader financial health and strategic direction.

Keywords

Calidi Biotherapeutics, CLDI, Form 4, Insider Trading, Andrew C. Jackson, CFO, Public Offering, Warrants, Equity Purchase, 10b5-1 Plan